Cover Image
市場調查報告書

類鐸受體3:開發中產品分析

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 366667
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
類鐸受體3:開發中產品分析 Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 78 Pages
簡介

本報告提供以類鐸受體3為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

類鐸受體3 (CD283 or TLR3) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Biomics Biotechnologies Co., Ltd.
  • Hemispherx Biopharma, Inc.
  • Idera Pharmaceuticals, Inc.
  • Innate Pharma S.A.
  • Johnson & Johnson
  • MultiCell Technologies, Inc.
  • Oncovir, Inc.
  • Tollys S.A.S

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0389TDB

Summary

Global Markets Direct's, 'Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2016', provides in depth analysis on Toll Like Receptor 3 (CD283 or TLR3) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
  • The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Toll Like Receptor 3 (CD283 or TLR3) Overview
  • Therapeutics Development
    • Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Stage of Development
    • Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Therapy Area
    • Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Indication
  • Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Companies
  • Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Universities/Institutes
  • Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
    • Biomics Biotechnologies Co., Ltd.
    • Hemispherx Biopharma, Inc.
    • Idera Pharmaceuticals, Inc.
    • Innate Pharma S.A.
    • Johnson & Johnson
    • MultiCell Technologies, Inc.
    • Oncovir, Inc.
    • Tollys S.A.S
  • Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
    • Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Agonize TLR-3 for Age Related Macular Degeneration - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNTO-3157 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Activate TLR3 for Atherosclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPH-33 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MCT-465 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Agonize TLR3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides to Agonize TLR3 for Infectious Disease and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Poly-ICLC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rabies vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rintatolimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TLR-3 for Infectious Disease and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stathmin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Toll Like Receptor 3 (CD283 or TLR3) - Dormant Projects
  • Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
  • Toll Like Receptor 3 (CD283 or TLR3) - Featured News & Press Releases
    • Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)" in Expert Review of Clinical Pharmacology
    • Jun 06, 2016: Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property
    • Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke
    • Feb 09, 2016: Hemispherx Biopharma Exploring Possible Research Program in Zika Virus Using Ampligen
    • Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant
    • Sep 28, 2015: Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen Formulations
    • Sep 23, 2015: Hemispherx Biopharma Reports Article by Senior Authors from Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen to Multiple Sclerosis
    • Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen
    • Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study
    • Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms
    • Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe
    • Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Division's Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations
    • May 26, 2015: Hemispherx Biopharma Europe : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease
    • May 11, 2015: Hemispherx Biopharma Europe Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)
    • Mar 24, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016
  • Pipeline by Hemispherx Biopharma, Inc., H2 2016
  • Pipeline by Idera Pharmaceuticals, Inc., H2 2016
  • Pipeline by Innate Pharma S.A., H2 2016
  • Pipeline by Johnson & Johnson, H2 2016
  • Pipeline by MultiCell Technologies, Inc., H2 2016
  • Pipeline by Oncovir, Inc., H2 2016
  • Pipeline by Tollys S.A.S, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top